Posters and Presentations
ZIFTOMENIB / MENIN INHIBITION
Ziftomenib in Relapsed / Refractory (R/R) NPM1-mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Clinical Activity and Safety Results from the Pivotal KOMET-001 Study
Ziftomenib in Relapsed/Refractory (R/R) NPM1-mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Clinical Activity and Safety Results from the Pivotal KOMET-001 Study
Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors after imatinib failure
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Menin inhibitor ziftomenib synergizes with imatinib in tyrosine kinase inhibitor (TKI)-resistant gastrointestinal stromal tumor models
Menin inhibitor ziftomenib synergizes with imatinib in tyrosine kinase inhibitor (TKI)-resistant gastrointestinal stromal tumor models
The Menin Inhibitor Ziftomenib Induces Insulin Production and Improves Insulin Sensitivity in a Rat Model of Type 2 Diabetes Mellitus (T2DM)
Clinical Pharmacology and Pharmacokinetic Profile of Ziftomenib, A Menin Inhibitor, In Adults With Relapsed/Refractory Acute Myeloid Leukemia
KOMET-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-R AML
Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutated AML (EHA 2023 Oral Encore)
Activity, tolerability and resistance profile of the menin inhibitor ziftomenib in adults with relapsed or refractory NPM1-mutated AML
Phase 1 study of ziftomenib in combination with venetoclax, venetoclax/azacitidine, or standard induction (7+3) chemotherapy in patients with acute myeloid leukemia
Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutated AML
Phase 1 Study of Ziftomenib in Combination with Venetoclax, Venetoclax/Azacitidine, or Standard Induction (7+3) Chemotherapy in Patients with Acute Myeloid Leukemia
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML
The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax
Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia
In vivo CRISPR screens identify dual function of MEN1 in regulating tumor-microenvironment interactions
Clinical-Stage Menin Inhibitor KO-539 is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A/MLL-r and NPM1-Mutant AML Models.
Preliminary Phase 1/2A Data From the KOMET-001 First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Novel Small Molecule Menin-MLL Inhibitor for Potential Treatment of MLL-rearranged Leukemias and NPM1/DNMT3A-mutant AML.
A Novel Small Molecule Menin-MLL Inhibitor for Potential Treatment of MLL-rearranged Leukemias.
Discovery of Novel Menin-MLL Small Molecule Inhibitors That Display High Potency and Selectivity in Vitro and in Vivo.
TIPIFARNIB / KO-2806 / FARNESYLTRANSFERASE INHIBITION
Farnesyl transferase inhibition restores RAS inhibitor sensitivity in tumors exhibiting innate or adaptive resistance
Farnesyl transferase inhibitor KO-2806 enhances the anti-tumor activity of cabozantinib in renal cell carcinoma
KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRASG12C NSCLC tumors to KRASG12C mutant-specific inhibitors through mTOR signaling inhibition
The next-generation farnesyl transferase inhibitor KO-2806 sensitizes colorectal cancers to pan-RAS inhibition
KO-2806, a Farnesyl Transferase Inhibitor, Re-sensitizes KRASG12C NSCLC Tumors to KRASG12C Mutant-Specific Inhibitors
FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors
A phase 1 clinical trial of the novel farnesyl transferase inhibitor KO-2806 (FIT-001) alone or as part of combination therapy for advanced solid tumors
A phase 2 study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN)
KO-2806, a next-generation farnesyltransferase inhibitor, potentiates the antitumor activity of cabozantinib in clear cell renal cell carcinoma models
The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma
The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRASG12D inhibition
Farnesyl Transferase Inhibitors – Evolution from Targeting HRAS to Overcoming Adaptive Resistance to Targeted Therapies
Tipifarnib synergizes with axitinib in clear cell renal cell carcinoma models
Tipifarnib synergizes with a TKI in clear cell renal cell carcinoma models
Combination of Tipifarnib with KRASG12C Inhibitors to Prevent Adaptive Resistance
HNSCCs overexpressing wild-type HRAS are sensitive to combined tipifarnib and alpelisib treatment
Using Tipifarnib to prevent resistance to targeted therapies in oncogene-addicted tumors
Targeting oncogenic HRAS in pediatric rhabdomyosarcoma
A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT-HN Trial)
Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC
Tipifarnib potentiates the antitumor effects of PI3Kα blockade in HNSCC via convergent inhibition of mTOR activity
A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT Trial)
Translating genotype to immunophenotype in HRAS mutated head and neck squamous cell carcinoma (HNSCC) to identify effective Tipifarnib partners for optimal patient outcomes
Antitumor activity of tipifarnib and alpelisib in HRAS-associated HNSCC
Final Results from KO-TIP-002 a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT02464228)
Antitumor activity of Tipifarnib and PI3K Pathway inhibitors in HRAS-associated HNSCC
Final results of a phase 2 study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
The AIM-HN Study: A registrational-directed study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations
Tipifarnib is Highly Active in Combination with Alpelisib in Models of HRAS/PI3K-dysregulated HNSCC
Preliminary Results From an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) and Other Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPNS)
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL): Preliminary Results from an Open-Label, Phase 2 Study
Preliminary Activity of Tipifarnib in Tumors of the Head & Neck, Salivary Gland, and Urothelial Tract With HRAS Mutations
The AIM-HN and SEQ-HN Study: A Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Tipifarnib, a Farnesyltransferase Inhibitor, for Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Preliminary Results From a Phase 2 Trial of Tipifarnib in Head and Neck Squamous Cell Carcinomas (HNSCCS) With HRAS Mutations
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
KIR3DL2 Mutation May Define a High Rate of Response of Aitl to Tipifarnib
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
CXCL12 and CXCR3 May Identify Complete Response in Acute Myeloid Leukemia Patients Treated With Tipifarnib
Mechanism of Action of the Farnesyltransferase Inhibitor Tipifarnib and its Potential Clinical Applications
Patient Reported Abdominal Pain as a Surrogate of the Clinical Benefit of Tipifarnib in Pancreatic Cancer Patients
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor cell lines
Tipifarnib is Highly Active in HRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Models
Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Squamous Cell Carcinomas (SCCS) With HRAS Mutations
Tipifarnib is Highly Active in HRAS-mutant Lung Squamous Cell Carcinoma Tumor Models
Pre-clinical Activity of Tipifarnib in Cutaneous T-cell Lymphoma
Preliminary Results from a Phase 2 Trial of Tipifarnib in HRAS mutant Head & Neck Squamous Cell Carcinomas (HNSCC)
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma
Preliminary Results From an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)
Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation
Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Tumors With HRAS Mutations.
Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Tumors With HRAS Mutations.
Preliminary Results From an Open-Label, Phase II Study of Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma.
Preliminary Results From an Open-Label, Phase II Study of Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma.
Tipifarnib is Highly Active in HRAS-mutant SCCHN Tumor Models.
Preliminary Evidence of Clinical Activity With Tipifarnib in Squamous Cell Carcinomas of the Head & Neck (SCCHN) With Hras Mutations.
Targeting the RAS-ERK Pathway.